miR-130a在心血管疾病中的研究进展  

Research Progress of miR-130a in Cardiovascular Diseases

作　　者：余明 陈涛 刘浙波 崔胜宇 徐林[1] 夏豪[1] YU Ming;CHEN Tao;LIU Zhebo;CUI Shengyu;XU Lin;XIA Hao(Department of Cardiology,Renmin Hospital of Wuhan University/Cardiovascular Research Institute,Wuhan University/Hubei Key Laboratory of Cardidogy,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院心内科武汉大学心血管病研究所心血管病湖北省重点实验室,武汉430060

出　　处：《医学综述》2020年第4期658-662,667,共6页Medical Recapitulate

摘　　要：心血管疾病是威胁人类生命健康的主要杀手之一。近年来,随着基因测序技术的进步及心血管疾病研究的深入,微RNA(miRNA)已成为心血管疾病领域的研究热点。循环中miRNA是一种内源性保守的非编码单链小(1~22个核苷酸) RNA,它是心脏发育和生理活动的关键调节因子,控制几乎所有与心血管系统相关的细胞类型(内皮细胞、心肌细胞、平滑肌细胞、炎症细胞和成纤维细胞等)的基本功能,可作为心血管疾病的诊断生物标志物。未来,应进一步探索miRNA作为心血管疾病治疗靶点的潜力,以及它们作为新生物标志物的用途。Cardiovascular disease is one of the major killers threatening human life and health. In recent years,with the development of gene sequencing technology and in-depth research on cardiovascular diseases,microRNA( miRNA) has become a research hotspot in the field. Circulating miRNA is an endogenous conserved single stranded small( 1-22 nucleotides),which is a key regulator of cardiac development and physiological activities,controlling basic function of almost all the cell types associated with cardiovascular system( endothelial cells,myocardial cells,smooth muscle cells,inflammatory cells and fibroblasts,etc.),and can be used as a diagnostic biomarker of cardiovascular diseases. In the future,the potential of miRNA as therapeutic targets for cardiovascular diseases and their use as new biomarkers should be further explored.

关 键 词：心血管疾病 miR-130a 生物标志物 调控作用 

分 类 号：R714.252[医药卫生—妇产科学]